Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Jakubik

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bratislavske Lekarske Listy|March 21, 2002
Transtrochanteric rotational osteotomy, section after SugiokaJ Vojtassak, T Jakubik
Journal of Chromatography|June 19, 1992
Gas chromatographic-mass spectrometric detection of trace amounts of organic compounds in the intravenous solution Infusio DarrowiJ Lesko, T Jakubik, A Michalkova
Journal of Cell Science|August 15, 2019
PI3Kβ is selectively required for growth factor-stimulated macropinocytosisGilbert Salloum, Charles T Jakubik, Zahra Erami, et al.
FEBS Letters|January 6, 2022
PIP<sub>3</sub> abundance overcomes PI3K signaling selectivity in invadopodiaCharles T Jakubik, Claire C Weckerly, Gerald R V Hammond, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
PNAS Nexus|January 30, 2023
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer modelsSheeba Jacob, Tia H Turner, Jinyang Cai, et al.
Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Cancer Cell|February 10, 2016
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationJungoh Ham, Carlotta Costa, Renata Sano, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bratislavske Lekarske Listy|March 21, 2002
Transtrochanteric rotational osteotomy, section after SugiokaJ Vojtassak, T Jakubik
Journal of Chromatography|June 19, 1992
Gas chromatographic-mass spectrometric detection of trace amounts of organic compounds in the intravenous solution Infusio DarrowiJ Lesko, T Jakubik, A Michalkova
Journal of Cell Science|August 15, 2019
PI3Kβ is selectively required for growth factor-stimulated macropinocytosisGilbert Salloum, Charles T Jakubik, Zahra Erami, et al.
FEBS Letters|January 6, 2022
PIP<sub>3</sub> abundance overcomes PI3K signaling selectivity in invadopodiaCharles T Jakubik, Claire C Weckerly, Gerald R V Hammond, et al.
Cancer Cell|December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancerCarlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
PNAS Nexus|January 30, 2023
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer modelsSheeba Jacob, Tia H Turner, Jinyang Cai, et al.
Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Cancer Cell|February 10, 2016
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationJungoh Ham, Carlotta Costa, Renata Sano, et al.
Pageof 1